PUBLIC COMPANY
saveUniversity of Texas MD Anderson Cancer Center
updated 2mo ago
community read0 votes
🐶 often sniffed alongside
top 2pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Preclinical
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- FDA panel endorses broader use of certain peptidesIn a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven peptides up for consideration despite a lack of substantive evidence supportin…biopharma_dive · 19d ago
- Trump administration warns more than 500 hospitals to provide more price information or face finesThe Trump administration has warned more than 500 hospitals that they are failing to provide the public with basic pricing information.stat · 2mo ago
- Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical PracticeSanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.onclive · 3mo ago
- FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLThe FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.onclive · 3mo ago
- Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLCourtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.onclive · 3mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 3mo ago
- UT MD Anderson Shares Latest Research BreakthroughsThe University of Texas MD Anderson Cancer Center released recent oncology research highlights.onclive · 3mo ago
- Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.onclive · 3mo ago
- Dr Pant on the Mechanism of Action of Daraxonrasib in PDACShubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.onclive · 3mo ago
- Dr Pant on Managing Toxicities With Daraxonrasib in PDACShubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.onclive · 3mo ago
comments(0)
5-min edit window · permanent after that